Claim136d4456010b339cd08f6b50103611b532e605e1d62dad2e33b6bce2d812e077·My Arguments

FDA analysis of 24 RCTs involving 4,582 children and adolescents found that the rate of suicidal thinking and behavior was 4% for those given an SSRI versus 2% for placebo, meaning approximately 1-3 additional patients per 100 treated developed treatment-emergent suicidality beyond baseline risk.

Evidence (1)

Intense Suicidal Thoughts and Self-Harm Following Escitalopram Treatment
Reports FDA findings of 4% vs 2% suicidality rate in SSRI vs placebo groups across 24 pediatric trials.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3195160/

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

Join & respond

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/136d4456010b339cd08f6b50103611b532e605e1d62dad2e33b6bce2d812e077"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.